Acrivon Therapeutics, Inc. (ACRV)
NASDAQ:ACRV
Want to see ACRV full AI Analyst Report?
ACRV Stock Chart & Stats
$1.78
-$0.20(-3.17%)
At close: 4:00 PM EST
$1.78
-$0.20(-3.17%)
Day’s Range― - ―
52-Week Range$1.05 - $3.56
Previous CloseN/A
Volume1.72K
Average Volume (3M)996.44K
Market Cap
$74.00M
Enterprise Value$20.54M
Total Cash (Recent Filing)$118.58M
Total Debt (Recent Filing)$2.71M
Price to Earnings (P/E)―
Beta1.77
Next Earnings
May 20, 2026EPS Estimate
-0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding38,744,446
10 Day Avg. Volume442,853
30 Day Avg. Volume996,436
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)0.82
Price to Sales (P/S)0.00
P/FCF Ratio-1.42
Enterprise Value/Market Cap0.28
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.24
Forecast
1Y Price Target
$13.67Price Target Upside667.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.1
Revenue Forecast (FY)$1.31M
Bulls Say, Bears Say
Bulls Say
Efficacy In Serous SubtypeACR-368 showed notably higher tumor response rates in serous endometrial cancer compared with other subtypes, indicating a strong efficacy signal in this high-risk patient group.
Mechanism Of ActionThe drug targets DNA repair vulnerabilities common in serous tumors, providing a clear scientific rationale for selective activity in that subgroup.
Regulatory Strategy And Trial DesignA registrational trial focused on serous disease has regulatory alignment and a proposed confirmatory design, creating a potential path toward accelerated approval if prospective results confirm earlier signals and enrollment without required pre-treatment biopsies could broaden patient access.
Bears Say
Addressable Market SizeSerous endometrial cancer represents only a minority of cases, which could limit the overall addressable market despite the high unmet need within that subgroup.
Development And Funding RiskUncertainty between pursuing monotherapy versus combination approaches and all-comer versus biomarker-selected strategies complicates the regulatory path and increases execution risk, while limited cash resources could pressure ongoing development.
Limited Evidence SizeCurrent efficacy findings derive from a small patient cohort and retrospective analyses, which may not translate into robust results in larger prospective trials.
Acrivon Therapeutics, Inc. News
ACRV FAQ
What was Acrivon Therapeutics, Inc.’s price range in the past 12 months?
Acrivon Therapeutics, Inc. lowest stock price was $1.05 and its highest was $3.56 in the past 12 months.
What is Acrivon Therapeutics, Inc.’s market cap?
Acrivon Therapeutics, Inc.’s market cap is $74.00M.
When is Acrivon Therapeutics, Inc.’s upcoming earnings report date?
Acrivon Therapeutics, Inc.’s upcoming earnings report date is May 20, 2026 which is in 21 days.
How were Acrivon Therapeutics, Inc.’s earnings last quarter?
Acrivon Therapeutics, Inc. released its earnings results on Mar 19, 2026. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.483 by -$0.007.
Is Acrivon Therapeutics, Inc. overvalued?
According to Wall Street analysts Acrivon Therapeutics, Inc.’s price is currently Undervalued.
Does Acrivon Therapeutics, Inc. pay dividends?
Acrivon Therapeutics, Inc. does not currently pay dividends.
What is Acrivon Therapeutics, Inc.’s EPS estimate?
Acrivon Therapeutics, Inc.’s EPS estimate is -0.53.
How many shares outstanding does Acrivon Therapeutics, Inc. have?
Acrivon Therapeutics, Inc. has 38,744,446 shares outstanding.
What happened to Acrivon Therapeutics, Inc.’s price movement after its last earnings report?
Acrivon Therapeutics, Inc. reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.483. Following the earnings report the stock price went up 3.659%.
Which hedge fund is a major shareholder of Acrivon Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ACRV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acrivon Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.67 (667.79% Upside)
$13.67 (667.79% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 6.7%
Last 30 Days ▼ 6.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-62.55%
12-Months-Change
Fundamentals
Return on Equity
-57.23%
Trailing 12-Months
Asset Growth
-33.46%
Trailing 12-Months
Company Description
Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
ACRV Stock 12 Month Forecast
Average Price Target
$13.67
▲(667.79% Upside)
Technical Analysis
Medicinova
―
Aligos Therapeutics
―
Genenta Science SpA Sponsored ADR
―
Immix Biopharma
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
46.14% Insiders
2.19% Mutual Funds
28.47% Other Institutional Investors
21.21% Public Companies and Individual Investors
Options Prices
Currently, No data available
---